Skip to content

Author

I. Rangraze

We have 5 of 63 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes

Evidence for approved and investigational oral incretin therapies, dual and triple receptor agonists, amylin-based strategies, established antidiabetic drugs, and adjunctive approaches targeting body composition are summarized.

Karolina Hoffmann, Weronika Pucek, Wiktoria Skrzypek et al. · 0 citations
Review Open access Sep 2026

Targeting the Gut–Bone Axis with Prebiotics, Probiotics, Synbiotics, and Postbiotics: From Mechanistic Plausibility to Clinical Bone Outcomes

Osteoporosis is a major skeletal disorder. Increasing evidence suggests that gut microbiota-derived mechanisms may contribute to bone remodeling. The biological rationale for a gut–bone axis is well supported, but the clinical relevance of microbiome-targeted interventions remains uncertain. In this narrative review, w...

Sorina Ispas, V. Maggio, A. Wali et al. · 0 citations
Review Open access Sep 2026

From Neonatal History to Adult Cardiovascular Risk: Preterm Birth as a Lifelong Risk Enhancer

Background: Preterm birth is increasingly recognized as an early-life exposure with potential cardiovascular consequences across the lifespan. Although improved neonatal care has increased survival among individuals born very and extremely preterm, birth history remains rarely incorporated into cardiovascular risk asse...

M. Patni, Malek Nasrallah, D. J. Al Tarawneh et al. · 0 citations
Review Open access Jan 2026

Microbiome‐Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response

Current preclinical and clinical evidence describing the gut–breast cancer axis and its mechanistic and translational relevance is summarized and current advances in microbiome‐targeted interventions including probiotics, dietary modulation, postbiotics, and fecal microbiota transplantation are discussed.

A. Wali, Sirajunisa Talath, I. Rangraze et al. · 0 citations
Review Open access Sep 2026

Pathological Complete Response to Nab-Paclitaxel–Containing Neoadjuvant Regimens in Early Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Within nab-paclitaxel-containing neoadjuvant backbones, checkpoint-inhibitor addition was associated with higher pCR in randomized comparative evidence, and should not be interpreted as a cross-regimen comparison because of clinical and methodological heterogeneity.

R. A. Salama, M. El-Tanani, S. A. Rabbani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.